製品番号: HY-N0008

Orcinol glucoside

(別名: Sakakin; サカキン)

1 Cited Publications

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Orcinol glucoside is an orally active, blood-brain barrier permeable osteoblast proliferation promoter that targets the Nrf2/Keap1, mTOR and p38 signaling pathways. Orcinol glucoside promotes Nrf2 nuclear translocation, upregulates antioxidant enzyme levels, enhances the phosphorylation of mTOR and p70S6K, and inhibits the enzymatic activity of HAS2 as well as the nuclear translocation of GR. Orcinol glucoside also alleviates oxidative stress, inhibits autophagic flux, osteoclastogenesis and TGF-β1-induced M2 polarization, while reducing collagen deposition and effectively promoting the proliferation, differentiation and mineralization of osteoblasts. Orcinol glucoside also exhibits anti-pulmonary fibrosis, anxiolytic and antidepressant activities. Orcinol glucoside can be used in the research of senile and glucocorticoid-induced osteoporosis, idiopathic pulmonary fibrosis (IPF), anxiety and other related diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.92%
CAS 番号: 21082-33-7
分子式: C₁₃H₁₈O₇
分子量:286.28

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Orcinol glucoside 構造式

CAS 番号: 21082-33-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Wnt アイソフォーム固有の製品をすべて表示 :

p38 MAPK アイソフォーム固有の製品をすべて表示 :

mTOR アイソフォーム固有の製品をすべて表示 :

TGF-β Receptor アイソフォーム固有の製品をすべて表示 :

体外実験

Orcinol glucoside (1-10 μM; 72 h) does not reduce the viability of H₂O₂-exposed RAW264.7 cells^[1].
Orcinol glucoside (1-10 μM; 72 h) dose-dependently inhibits the differentiation and TRAP activity of RANKL- and H₂O₂-induced RAW264.7 osteoclasts^[1].
Orcinol glucoside (5-10 μM; 48 h pre-incubation with RANKL before 4 h H₂O₂ exposure) activates the mTOR pathway in RANKL- and H₂O₂-induced RAW264.7 osteoclasts, increasing phosphorylation of mTOR and p70S6K^[1].
Orcinol glucoside (10-100 nM; 72 h) promotes proliferation of primary mouse osteoblast cells in a dose-dependent manner at concentrations of 10, 50, and 100 nM over 72 h^[2].
Orcinol glucoside (10-100 nM) upregulates p38 phosphorylation and the expression of osteogenic-related proteins (Collagen I, Runx2, Osx, Dlx5) in primary mouse osteoblast cells in vitro in a dose-dependent manner at concentrations of 10, 50, and 100 nM^[2].
Orcinol glucoside (0-100 µM; 48 h) is non-toxic to NIH/3T3 mouse fibroblasts and HFL-1 human fibroblasts at concentrations ranging from 0 to 100 µM after 48 h incubation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

murine macrophage RAW264.7 cells
Concentration:

1-10 μM
Incubation Time:

72 h
Result:

Exerted no cytotoxic effects on RAW264.7 cells, with cell viability remaining comparable to control groups.

Cell Differentiation Assay^[1]

Cell Line:

RANKL- and H₂O₂-induced RAW264.7 cells
Concentration:

1-10 μM
Incubation Time:

72 h
Result:

Decreased the number of TRAP-positive multinucleated osteoclasts and reduced TRAP activity in a dose-dependent manner compared to the H₂O₂-only treated group.

体内実験

Orcinol glucoside (50-100 mg/kg, intragastric administration; daily dosing; for 10 consecutive weeks) alleviates senile osteoporosis in SAMP6 mice, significantly improves bone microstructure, reduces the levels of bone resorption biomarkers, and regulates oxidative stress and autophagy via the Nrf2/Keap1 and mTOR signaling pathways^[1].
Orcinol glucoside (5-20 mg/kg, intragastric administration; daily dosing; for 8 consecutive weeks) dose-dependently increases BMD, BV/TV, Tb.Th and Tb.N in dexamethasone-induced osteoporotic mice by activating the p38 signaling pathway and upregulating downstream osteogenic proteins^[2].
Orcinol glucoside (5 mg/kg, intragastric administration, once daily for 5 consecutive weeks) improves the bone microstructure and increases osteogenic biomarkers in dexamethasone-induced osteoporotic mice by activating p38, while p38 inhibitors block these effects^[2].
Orcinol glucoside (25-100 mg/kg; p.o.; once daily; for 14 consecutive days) dose-dependently alleviates bleomycin-induced pulmonary fibrosis in male C57BL/6J mice by inhibiting the expression of fibrosis markers, HA accumulation, and TGF-β₁ production, with an exposure-response relationship observed across different administration doses^[3].
Orcinol glucoside (5-20 mg/kg; p.o.; single administration) exhibits anxiolytic activity in mice without inducing sedative effects^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 (male, 8 weeks old, dexamethasone-induced osteoporosis)^[2]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

i.g.; daily; 8 weeks
Result:

Increased bone mineral density (BMD), trabecular bone volume fraction (BV/TV), trabecular thickness (Tb.Th), and trabecular number (Tb.N) in a dose-dependent manner compared to the dexamethasone-only group.
Reversed dexamethasone-induced reductions in serum osteoblast-associated markers type I procollagen amino-terminal extension peptide (PINP) and alkaline phosphatase (ALP).
Increased femoral tissue expression of p38, phosphorylated p38 (p-p38), Collagen I, Runx2, Osx, Dlx5, glucocorticoid receptor (GR), and phosphorylated GR Ser226 (p-GR226).

Animal Model:

CD-1 (male, 18-22 g)^[4]
Dosage:

5 mg/kg; 10 mg/kg; 20 mg/kg
Administration:

p.o.; single dose
Result:

Significantly increased the time spent in open arms and number of entries into open arms in the elevated plus-maze test compared to vehicle control.
Significantly increased the number of head-dips in the hole-board test compared to vehicle control (at 5 and 10 mg/kg).
Did not cause significant changes in mouse locomotor counts in the open-field test compared to vehicle control.

化学情報

CAS 番号 21082-33-7
性状 Solid
分子量 286.28
分子式 C₁₃H₁₈O₇
Color White to off-white
SMILES

CC1=CC(O)=CC(O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)CO)=C1
別名

Sakakin; サカキン
Structure Classification
- Phenols
- Monophenols
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Int J Mol Med

Orcinol glucoside ameliorates pulmonary fibrosis by suppressing hyaluronic acid synthesis and macrophage M2 polarization via targeting hyaluronic acid synthase 2. [Abstract]

2026 Apr;57(4):93. PMID: 41685577

溶剤 & 溶解度

体外:

DMSO : 125 mg/mL (436.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4931 mL

17.4654 mL

34.9308 mL

5 mM

0.6986 mL

3.4931 mL

6.9862 mL

10 mM

0.3493 mL

1.7465 mL

3.4931 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Gong W, et al. Orcinol Glucoside Improves Senile Osteoporosis through Attenuating Oxidative Stress and Autophagy of Osteoclast via Activating Nrf2/Keap1 and mTOR Signaling Pathway. Oxid Med Cell Longev. 2022;2022:5410377. Published 2022 May 9. [Content Brief]

[2]. He XY, et al. Orcinol glucoside targeted p38 as an agonist to promote osteogenesis and protect glucocorticoid-induced osteoporosis. Phytomedicine. 2023;119:154953. [Content Brief]

[3]. Li C, et al. Orcinol glucoside ameliorates pulmonary fibrosis by suppressing hyaluronic acid synthesis and macrophage M2 polarization via targeting hyaluronic acid synthase 2. Int J Mol Med. 2026;57(4):93. [Content Brief]

[4]. Wang X, et al. Anxiolytic effects of orcinol glucoside and orcinol monohydrate in mice. Pharm Biol. 2015;53(6):876-881. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4931 mL	17.4654 mL	34.9308 mL	87.3271 mL
	5 mM	0.6986 mL	3.4931 mL	6.9862 mL	17.4654 mL
	10 mM	0.3493 mL	1.7465 mL	3.4931 mL	8.7327 mL
	15 mM	0.2329 mL	1.1644 mL	2.3287 mL	5.8218 mL
	20 mM	0.1747 mL	0.8733 mL	1.7465 mL	4.3664 mL
	25 mM	0.1397 mL	0.6986 mL	1.3972 mL	3.4931 mL
	30 mM	0.1164 mL	0.5822 mL	1.1644 mL	2.9109 mL
	40 mM	0.0873 mL	0.4366 mL	0.8733 mL	2.1832 mL
	50 mM	0.0699 mL	0.3493 mL	0.6986 mL	1.7465 mL
	60 mM	0.0582 mL	0.2911 mL	0.5822 mL	1.4555 mL
	80 mM	0.0437 mL	0.2183 mL	0.4366 mL	1.0916 mL
	100 mM	0.0349 mL	0.1747 mL	0.3493 mL	0.8733 mL

Keywords

Orcinol glucoside

1 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Orcinol glucoside

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Phenols Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

3D Diverse Fragment Library

MedChemExpress（MCE）の使用を引用している文献 Orcinol glucoside

Wnt アイソフォーム固有の製品をすべて表示

p38 MAPK アイソフォーム固有の製品をすべて表示

mTOR アイソフォーム固有の製品をすべて表示

TGF-β Receptor アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (1)